Ani-survivin DNAzymes Inhibit Cell Proliferation and Migration in Breast Cancer Cell Line MCF-7

Zhang, Min; Sun, Yun-Yu; Luo, Shihua

doi:10.7314/apjcp.2012.13.12.6233

Cited by 8 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Survivin, a member of the IAP (inhibitor of apoptosis proteins) family, is highly associated with poor prognosis, decreased apoptosis and increased resistance to drugs in breast cancer cells. 29 Figure S2h) and SEM images. This result indicated that the size of DNFs can be finetuned by adjusting the reaction time.…”

Section: Construction and Characterization Of The Dnfsmentioning

confidence: 99%

Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer therapy

Jin

Liu

et al. 2017

NPG Asia Mater

View full text Add to dashboard Cite

Safety and efficiency remain the critical hurdles hindering the practical application of gene agents, even though great effort has been made to develop various gene carriers. Herein, we present a novel biodegradable cancer therapeutic system based on DNA nanoflowers (DNFs) for targeted dual gene silencing. The therapeutic system was constructed by copying a rolling circle amplification template to produce long single-stranded DNAs with cell targeting and dual gene-silencing capability. The structure of the DNFs collapsed at acidic pH due to the decomposition of the co-assembled magnesium pyrophosphate, generating Mg 2+ ions that act as cofactors for the DNAzymes and increase their ability to recognize and cleave target mRNAs. In vitro and in vivo studies demonstrated that the multifunctional DNFs showed promise for targeted cancer cell recognition, gene silencing, induction of apoptosis and inhibition of tumor growth. Considering the enhanced therapeutic effect and biocompatibility of this therapeutic platform, it is anticipated to be of great interest for the clinical treatment of cancers.

show abstract

Section: Construction and Characterization Of The Dnfsmentioning

confidence: 99%

Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer therapy

Jin

Liu

et al. 2017

NPG Asia Mater

View full text Add to dashboard Cite

show abstract

“…DRz1 exhibited a profound effect in inhibiting cell proliferation, inducing late-stage apoptosis, and suppressing motility and migration of MCF-7 cells. The downregulation of the expression of procaspase-3 and procaspase-9 and concomitant increase in caspase-3 and caspase-9 suggested the probable caspase-dependent apoptosis by DRz1 through the intrinsic and mitochondrial pathway [68].…”

Section: Dnazymes Targeting Apoptosismentioning

confidence: 94%

DNAzymes, Novel Therapeutic Agents in Cancer Therapy: A Review of Concepts to Applications

Thomas

Gaminda

Jayasinghe

et al. 2021

Journal of Nucleic Acids

View full text Add to dashboard Cite

The past few decades have witnessed a rapid evolution in cancer drug research which is aimed at developing active biological interventions to regulate cancer-specific molecular targets. Nucleic acid-based therapeutics, including ribozymes, antisense oligonucleotides, small interference RNA (siRNA), aptamer, and DNAzymes, have emerged as promising candidates regulating cancer-specific genes at either the transcriptional or posttranscriptional level. Gene-specific catalytic DNA molecules, or DNAzymes, have shown promise as a therapeutic intervention against cancer in various in vitro and in vivo models, expediting towards clinical applications. DNAzymes are single-stranded catalytic DNA that has not been observed in nature, and they are synthesized through in vitro selection processes from a large pool of random DNA libraries. The intrinsic properties of DNAzymes like small molecular weight, higher stability, excellent programmability, diversity, and low cost have brought them to the forefront of the nucleic acid-based therapeutic arsenal available for cancers. In recent years, considerable efforts have been undertaken to assess a variety of DNAzymes against different cancers. However, their therapeutic application is constrained by the low delivery efficiency, cellular uptake, and target detection within the tumour microenvironment. Thus, there is a pursuit to identify efficient delivery methods in vivo before the full potential of DNAzymes in cancer therapy is realized. In this light, a review of the recent advances in the use of DNAzymes against cancers in preclinical and clinical settings is valuable to understand its potential as effective cancer therapy. We have thus sought to firstly provide a brief overview of construction and recent improvements in the design of DNAzymes. Secondly, this review stipulates the efficacy, safety, and tolerability of DNAzymes developed against major hallmarks of cancers tested in preclinical and clinical settings. Lastly, the recent advances in DNAzyme delivery systems along with the challenges and prospects for the clinical application of DNAzymes as cancer therapy are also discussed.

show abstract

“…The DNAzymes inhibited the expression of p210 bcr‑abl protein by 40% in K562 cells and specifically inhibited the growth of bcr-abl -positive cells by 53–80% . Since then, the development of DNAzymes advances cancer therapy by modulating cancer cell proliferation/survival, − angiogenesis, , ECM degradation, , and metastasis. ,, …”

Section: Nanozyme-tumor Immune Microenvironment Interactionsmentioning

confidence: 99%

Nanozymes for Catalytic Cancer Immunotherapy

Qiu

Wang

2020

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Nanozymes are nanoparticles with enzyme-mimicking properties. With the intrinsic catalytic properties, nanozymes are endowed with merits to modulate the immunosuppression of tumor immune microenvironment (TIME), mainly through altering reactive oxygen and nitrogen species (ROS/RNS) level. Besides redox imbalance, nanozymes can modulate other features of TIME, such as hypoxia. Modulations of TIME enabled by nanozymes can improve the effectiveness and efficiency of cancer therapies, especially immunotherapy. Two types of nanozymes, metal/metal oxide nanozymes and deoxyribozymes (DNAzymes) are currently investigated in cancer immunotherapy. They either act as standalone therapeutics or synergize with other therapeutic strategies to enhance antitumor effects. This Review summarizes the common nanozymes and their enzymatic properties, their interactions with TIME, and recent achievements of using nanozymes in cancer immunotherapy.

show abstract

Ani-survivin DNAzymes Inhibit Cell Proliferation and Migration in Breast Cancer Cell Line MCF-7

Cited by 8 publications

References 15 publications

Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer therapy

Biodegradable, multifunctional DNAzyme nanoflowers for enhanced cancer therapy

DNAzymes, Novel Therapeutic Agents in Cancer Therapy: A Review of Concepts to Applications

Nanozymes for Catalytic Cancer Immunotherapy

Contact Info

Product

Resources

About